Join our daily newsletter At The Bell to receive exclusive market insights
- Medlab Clinical (MDC) receives certification to import its NanaBis drug into the United Kingdom, helping pave the way to receiving market authority in the country
- The biotech company received the import certificate from the UK Home Office and will now apply for export certification to ship NanaBis from Canberra
- Nanabis is a cannabis-based drug being developed for cancer bone pain management
- The export certification could take 28 days to process, but once the drug arrives in the UK, it will be used in a Named Patient Program
- MDC shares end the trading day 5.19 per cent higher at $8.10 per share
Medlab Clinical (MDC) has received certification to import its NanaBis drug into the United Kingdom, helping pave the way to receiving market authority in the country.
The biotech company received the import certificate from the UK Home Office and will now apply for export certification to ship NanaBis from Canberra.
NanaBis, which is being called NanaDol for exporting to the UK, is a cannabis-based drug being developed for cancer bone pain management.
The company said the UK was a “NanaBis clinical trial territory” and that obtaining market authority for the drug in the country was a priority.
“It’s great to be able to expand the successes we have had with NanaBis to the UK people,” Medlab CEO Sean Hall said.
“As we recently announced, those data points across 1100 Australian patients were very encouraging.
“We are looking forward to replicating those success stories.”
The export certification out of Canberra could take up to 28 days to process, but once Nanadol is exported to the UK, it will be used in a Named Patient Program.
MDC shares ended the trading day 5.19 per cent higher at $8.10 per share.
